Stellar Biotech starts expansion project at its protein production plant

Cancer cells image
Stellar Biotechnologies makes a key protein used in the development of a number of immunotherapies. (Max Pixel/CC0)

Stellar Biotechnologies, which makes a key protein used in the development of a number of immunotherapies, is expanding its manufacturing facility at Port of Hueneme in California.

The company said its production expansion includes 10,000 square feet of renovated space for its aquaculture production as well as other improvements.

Stellar manufactures a medical-grade protein called KLH which is made in aquaculture from a marine mollusk—the Giant Keyhole Limpet. It is used in developing immunotherapy drugs targeting Alzheimer's, lupus and cancers, among other diseases.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

"We are preparing our infrastructure to support pharmaceutical industry standards for commercial drugs, including purity, controls and traceability," Frank Oakes, Stellar’s president and CEO, said in a statement. "By staging these investments, we can prepare the business for growth while minimizing upfront costs.”

In addition to the planned expansion at Port Hueneme, which is located near Los Angeles, Stellar said it is looking to set up operations in Baja California that would include the development of regional marine resources, aquaculture and raw material processing.

Suggested Articles

Thermo Fisher Scientific's pharma services group is establishing itself as a gene therapy manufacturer with a $1.7 billion cash deal for Brammer Bio.

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.